Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Other Accumulated Expenses (2016 - 2025)

Ocular Therapeutix (OCUL) has 13 years of Other Accumulated Expenses data on record, last reported at $1.9 million in Q4 2025.

  • For Q4 2025, Other Accumulated Expenses fell 6.76% year-over-year to $1.9 million; the TTM value through Dec 2025 reached $1.9 million, down 6.76%, while the annual FY2025 figure was $1.9 million, 6.76% down from the prior year.
  • Other Accumulated Expenses reached $1.9 million in Q4 2025 per OCUL's latest filing, up from $1.9 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $2.1 million in Q4 2024 and bottomed at $699000.0 in Q1 2021.
  • Average Other Accumulated Expenses over 5 years is $1.4 million, with a median of $1.5 million recorded in 2023.
  • Peak YoY movement for Other Accumulated Expenses: tumbled 35.58% in 2021, then soared 61.58% in 2024.
  • A 5-year view of Other Accumulated Expenses shows it stood at $1.1 million in 2021, then rose by 11.13% to $1.2 million in 2022, then grew by 24.19% to $1.5 million in 2023, then soared by 34.75% to $2.1 million in 2024, then decreased by 6.76% to $1.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Accumulated Expenses were $1.9 million in Q4 2025, $1.9 million in Q3 2025, and $1.7 million in Q2 2025.